31 results on '"Trotman J."'
Search Results
2. MY HODGKIN, MY HEALTH: FEASIBILITY OF A MOBILE APPLICATION TO COLLECT LONG TERM FOLLOW UP DATA ABOUT HODGKIN PATIENTS
3. PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.
4. ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
5. MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.
6. Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial.
7. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)
8. INTRATUMORAL T‐CELLS HAVE A DIFFERENTIAL IMPACT ON FDG‐PET PARAMETERS IN FOLLICULAR LYMPHOMA
9. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY
10. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA
11. SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL
12. WhiMSICAL (WALDENSTRÖM'S MACROGLOBULINEMIA STUDY INVOLVING CArt-wheeL): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE
13. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)
14. PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
15. ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL.
16. Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network.
17. Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL.
18. FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY
19. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY
20. INCREASING CROSS-REFERRAL AND RECRUITMENT TO CLINICAL TRIALS: A NEW APProach
21. PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY
22. RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY
23. RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033).
24. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study
25. REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP
26. APPLICATION OF a GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)
27. PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS
28. OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033)
29. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
30. Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.
31. Women in Lymphoma: A 4-year journey in promoting gender equity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.